ACT's product pipeline includes synthetic vaccines utilizing our proprietary LbL technology for Respiratory Syncytial Virus (RSV) and malaria. Both vaccine candidates are in pre-clinical development and ACT is currently preparing an IND filing to conduct Phase I human trials of its RSV vaccine.

Respiratory syncytial virus (RSV) is the most important cause of severe lower respiratory tract illness in infants and is as significant an infection in the elderly as influenza. RSV is the cause of one-fifth of all lower respiratory tract infections worldwide. The estimated total direct medical costs for RSV-associated infant hospitalizations averages more than $750M per year in the U.S. alone. There are currently no approved vaccines for RSV, and with no effective treatment available and the only preventative medication considered far too expensive to be widely used, the need for an effective vaccine is high.

ACT’s RSV vaccine contains the RSV-G chemokine motif and other important RSV epitopes that are known to promote protective immune responses. We have demonstrated potency (immune response) and efficacy (protection from viral challenge) of our RSV vaccine candidate in the mouse (with both intradermal and intranasal routes of administration) and in the cotton rat, which is widely accepted as the most relevant preclinical model for human RSV infection and disease.  This effort has attracted funding from the National Institutes of Allergy and Infectious Disease (NIAID), including a Small Business Innovation Research (SBIR) grant awarded to ACT. Our research partners on the RSV vaccine include the US Centers for Disease Control and Prevention (CDC).

Malaria is one of the major diseases in the developing world, with 200-500 million new infections and over 1 million deaths each year, primarily in young children in Africa. The parasite Plasmodium falciparum is the causative agent of human malaria in sub-Saharan Africa and other tropical areas. ACT’s malaria vaccine incorporates T1BT* epitopes from the CS protein of the sporozoite stage of P. falciparum that are recognized by antibodies and T-cells of protected hosts. We have shown that mice immunized with our vaccine candidates develop CS-specific antibody and cellular immune responses and are protected from challenge with live Plasmodium. Since our LbL vaccine candidates generate a highly immunogenic response with small doses and without use of adjuvants, they do not elicit harmful inflammatory responses even while inducing protection against the parasite. This project has attracted SBIR funding from the NIAID.